North America Respiratory Inhalers Market Report and Forecast 2024-2032

North America Respiratory Inhalers Market Outlook

North America respiratory inhalers market size is expected to grow at a CAGR of 5.90% during the forecast period of 2024-2032, driven by the rising prevalence of respiratory diseases along and the development of advanced inhaler devices in the region.

Key Takeaways

• It is estimated that around 15.7 million Americans which accounts for 6.4% of the population have been diagnosed with chronic obstructive pulmonary disease (COPD).  This growing patient base is expected to directly impact market demand in the region.

• One of the major North America respiratory inhalers market trends is the rise in strategic partnerships among the key market players to improve the accessibility of their inhaler devices. In June 2023, Teva Pharmaceuticals Industries Ltd.  partnered with Phil Inc. to improve the accessibility of their Digihaler products for asthma patients using the PhilRx Patient Access Platform.

• The favorable regulatory environment in the region is likely to boost market size. In January 2023 , the FDA approved AstraZeneca's rescue inhaler, Airsupra. The pressurized metered-dose inhaler for adult use offers a treatment option that can both manage the symptoms and the underlying inflammation during an asthma attack.

North America Respiratory Inhalers Market Analysis

Respiratory inhalers are portable, hand-held devices that can deliver medication directly to the lungs. These devices help in the treatment and management of chronic obstructive pulmonary disease (COPD) and asthma symptoms. Administration through inhalation offers a distinct advantage by ensuring that the maximum concentration of the medicine reaches the target tissue. Thus, the ability of these inhaler devices to deliver the highest potential therapeutic effect of the drug coupled with advancements in inhaler technology is expected to propel the North America respiratory inhalers market demand in the forecast period.

In North America, various respiratory conditions are becoming increasingly common, driven by factors such as smoking, air pollution, and the growing aging population. It is estimated that around 15.7 million Americans accounting for 6.4% of the population have been diagnosed with chronic obstructive pulmonary disease (COPD).  Moreover, it is reported that COPD ranks as the fourth leading cause of death in the United States. Since inhaled medications stands as the primary treatment for COPD, along with the inhaler technique necessary to boost the medication efficacy, the demand for respiratory inhalers is likely to witness a surge in coming years. Moreover, it is further fuelled by the growing patient base in the region.

Several leading market players are entering into strategic partnerships to improve the accessibility of their inhaler device portfolios, which is anticipated to contribute to North America respiratory inhalers market growth. For instance, in June 2023, Teva Pharmaceuticals’  partnered with a United States-based health-tech startup Phil Inc. to facilitate increased access to their Digihaler products (the first smart inhaler system that records objective inhaler data) using the PhilRx Patient Access Platform. The patient-centric technology solution by Phil Inc., offers complete visibility into the entire prescription lifecycle, streamlining prescription filling and medication management for asthma patients. Integration of such technologically advanced platforms is expected to enhance the consumer experience as well as improve patient outcomes, thereby elevating the market value.

The favorable regulatory environment is facilitating the introduction of new inhaler products in the region, which is expected to boost the North America respiratory inhalers market share. In January 2023 , the United States Food and Drug Administration (FDA) approved a first-in-class rescue inhaler Airsupra, co-developed by AstraZeneca and Avillion LLP (a drug development company). The combination therapy received FDA approval based on the positive results demonstrated in the phase III trials called MANDALA and DENALI. The pressurized metered-dose inhaler for adult use contains both albuterol and budesonide, thus, it provides a treatment option that can manage the symptoms as well as the underlying inflammation during an asthma attack.

North America Respiratory Inhalers Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

North America Respiratory Inhalers Market: Competitor Landscape

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• AstraZeneca Plc

• Beximco Pharmaceuticals Ltd.

• Boehringer Ingelheim International GmbH

• Cipla Ltd

• GSK Plc (GlaxoSmithKline Plc)

• Koninklijke Philips NV

• OMRON Corp

• PARI Respiratory Equipment, Inc.

• Teva Pharmaceutical Industries Ltd

• OPKO Health, Inc

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report